These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 29972336)
21. Interactions between artemisinin derivatives and P-glycoprotein. Wang Y; Li Y; Shang D; Efferth T Phytomedicine; 2019 Jul; 60():152998. PubMed ID: 31301971 [TBL] [Abstract][Full Text] [Related]
22. Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells. Chang YT; Wang CCN; Wang JY; Lee TE; Cheng YY; Morris-Natschke SL; Lee KH; Hung CC Phytomedicine; 2019 Feb; 53():252-262. PubMed ID: 30668405 [TBL] [Abstract][Full Text] [Related]
23. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion. Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386 [TBL] [Abstract][Full Text] [Related]
24. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355 [TBL] [Abstract][Full Text] [Related]
25. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Pérez-Tomás R Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198 [TBL] [Abstract][Full Text] [Related]
26. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547 [TBL] [Abstract][Full Text] [Related]
27. Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca Sun Y; Wang C; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Peng J; Liu K J Cell Physiol; 2018 Apr; 233(4):3066-3079. PubMed ID: 28681913 [TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. Mao C; Li F; Zhao Y; Debinski W; Ming X Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297 [TBL] [Abstract][Full Text] [Related]
29. Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo. Wang J; Li Y; Wang L; Wang X; Tu P Drug Deliv; 2018 Nov; 25(1):330-340. PubMed ID: 29350064 [TBL] [Abstract][Full Text] [Related]
30. Tyrosine Kinase Inhibitors Imatinib and Erlotinib Increase Apoptosis of Antimitotic Drug-resistant KBV20C Cells Without Inhibiting P-gp. Kim JY; Kim HS; Yoon S Anticancer Res; 2019 Jul; 39(7):3785-3793. PubMed ID: 31262905 [TBL] [Abstract][Full Text] [Related]
31. Redox-sensitive and hyaluronic acid functionalized liposomes for cytoplasmic drug delivery to osteosarcoma in animal models. Chi Y; Yin X; Sun K; Feng S; Liu J; Chen D; Guo C; Wu Z J Control Release; 2017 Sep; 261():113-125. PubMed ID: 28666726 [TBL] [Abstract][Full Text] [Related]
32. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment. Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537 [TBL] [Abstract][Full Text] [Related]
33. Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer. Yuan J; Yin Z; Tan L; Zhu W; Tao K; Wang G; Shi W; Gao J Cancer Lett; 2019 Aug; 457():28-39. PubMed ID: 31078735 [TBL] [Abstract][Full Text] [Related]
34. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357 [TBL] [Abstract][Full Text] [Related]
35. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells. Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553 [TBL] [Abstract][Full Text] [Related]
36. TM2, a novel semi-synthetic taxoid, exerts anti-MDR activity in NSCLC by inhibiting P-gp function and stabilizing microtubule polymerization. Jia L; Gao X; Fang Y; Zhang H; Wang L; Tang X; Yang J; Wu C Apoptosis; 2022 Dec; 27(11-12):1015-1030. PubMed ID: 36107354 [TBL] [Abstract][Full Text] [Related]
37. A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity. Zhou H; Lv S; Zhang D; Deng M; Zhang X; Tang Z; Chen X Acta Biomater; 2018 Jun; 73():388-399. PubMed ID: 29694920 [TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Binkhathlan Z; Lavasanifar A Curr Cancer Drug Targets; 2013 Mar; 13(3):326-46. PubMed ID: 23369096 [TBL] [Abstract][Full Text] [Related]
39. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution. Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562 [TBL] [Abstract][Full Text] [Related]
40. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]